WO2023049888 - BENZIMIDAZOLES AS MODULATORS OF IL-17
National phase entry:
Publication Number
WO/2023/049888
Publication Date
30.03.2023
International Application No.
PCT/US2022/077003
International Filing Date
26.09.2022
Title **
[English]
BENZIMIDAZOLES AS MODULATORS OF IL-17
[French]
BENZIMIDAZOLES UTILISÉS EN TANT QUE MODULATEURS D'IL-17
Applicants **
JANSSEN PHARMACEUTICA NV
Inventors
DECKHUT, Charlotte, Pooley
BEHENNA, Douglas, C.
BEMBENEK, Scott
GOLDBERG, Steven, D.
JACKSON, Paul, F.
KEITH, John
LOSKOT, Steven, A.
MARTIN, Connor
MCCARVER, Stefan
MEDUNA, Steven, P.
RHORER, Timothy, B.
SHIH, Amy, Y.
TANIS, Virginia, M.
WOODS, Craig, R.
XUE, Xiaohua
Priority Data
63/248,569
27.09.2021
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 10780 | |
| EPO | Filing, Examination, Granting | 99868 | |
| Japan | Filing, Examination, Granting | 4680 | |
| South Korea | Filing, Examination, Granting | 6818 | |
| USA | Filing, Examination, Granting | 26340 |
Total:
148,486
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
are defined in the specification, as well as methods of making and using the compounds disclosed herein for treating or ameliorating an IL-17 mediated syndrome, disorder and/or disease.[French]
étant tels que définis dans la description, ainsi que des procédés de fabrication et d'utilisation des composés de l'invention pour traiter ou améliorer un syndrome, un trouble et/ou une maladie à médiation par IL-17.